Medtronic pulseselect pfa system demonstrates impressive results in landmark pulsed af global ide trial

Acc.23/wcc late-breaking data: pulsed af, one of the most rigorously executed pfa clinical studies to date, exceeds safety and efficacy performance goals in the treatment of paroxysmal and persistent atrial fibrillation dublin and new orleans , march 6, 2023 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced that its pulseselect™ pulsed field ablation (pfa) system exceeded its safety performance goal, with an adverse event rate of 0.7%, one of the lowest adverse event rates of any prior u.s. fda investigational device exemption (ide) trial for atrial fibrillation (af) ablation or any multi-center pfa study. pulsed af exceeded the threshold for its efficacy performance goal and further, clinical success, freedom from recurrence of any symptomatic atrial arrhythmias, was at least 80% for each patient cohort.
MDT Ratings Summary
MDT Quant Ranking